Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

NCT05818085 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout

Interventions

DRUG: ABP-671
DRUG: Allopurinol
OTHER: Placebo

Sponsor

Atom Therapeutics Co., Ltd